With PCOS, you’re likely well aware of the difficulty that comes with the weight and metabolic aspects of PCOS. It’s hard to lose weight with insulin resistance, weight gain, irregular periods, and hormonal issues – it all goes hand-in-hand, making any sort of weight loss strategy less than useful.
GLP-1 drugs have gained quite a bit of popularity among the PCOS community, and for good reason, too. But what’s even better, the scientific literature is becoming more convincing. So, which GLP-1 should you take for PCOS? That depends entirely on your symptoms, your level of insulin resistance, your access to insurance, and your own goals for therapy.
This is what the science says right now. Want more information about GLP-1 drugs and who may benefit from taking them? Check out glpweightloss.online.
Why GLP-1 Medications Are Relevant to PCOS
Polycystic Ovary Syndrome (PCOS) is the most prevalent hormonal disorder among reproductive-age women, affecting up to 6% to 20% of women globally. Although it is known for its characteristic features of irregular menstrual cycles, hyperandrogenism, and polycystic ovaries, its metabolic basis should not be overlooked.
About 70% of women with PCOS suffer from insulin resistance, regardless of their being overweight. Insulin resistance leads to excessive androgen levels, disrupts the process of ovulation, causes visceral fat accumulation, and hinders effective weight loss efforts.
GLP-1 drugs tackle this head-on. These regulate glucose level dependency in a glucose-dependent way, improve insulin resistance, cause significant weight reduction, and prevent the development of hyperinsulinemia and excess androgens, which are responsible for PCOS. The usage of GLP-1 drugs among PCOS women has skyrocketed from 2.4% in 2021 up to 17.6% in 2025 – a rise of more than seven times, based on Truveta data.
However, one must clarify at once: there is no such FDA-approved drug for PCOS use at the moment. All prescriptions for PCOS women are done off-label based on FDA approval for obesity and type 2 diabetes, with certain body mass index criteria. At the same time, the research data on their application accumulates fast.
How GLP-1 Medications Help PCOS Specifically
The advantages of using GLP-1 drugs among women with PCOS extend far beyond just reducing excess weight. Their mechanism of action suits well with the nature of PCOS:
- Insulin resistance improvement – Insulin-reducing effects, HOMA-IR enhancement, and blood glucose normalization happen due to GLP-1 medication. Since PCOS is caused by insulin resistance in the first place, this factor becomes critical in the treatment of PCOS.
- Androgen reduction – The sensitivity to insulin decreases, and therefore, the increased androgenic effects of the hormone responsible for hirsutism, acne, and alopecia decrease. According to the 2024 meta-analysis of five clinical trials concerning PCOS, GLP-1 analogues decreased the levels of free testosterone by 28 percent.
- Menstrual cycle restoration – Cycle regulation is one of the most commonly described advantages of GLP-1 medication. For instance, according to one clinical trial of semaglutide treatment for PCOS patients, 80 percent of responders showed a regulated menstrual cycle as a result of treatment with semaglutide. In another clinical trial of liraglutide treatment for PCOS, 82 percent of treated females had their menstrual cycle regulated.
- Improved ovulation and fertility – It has been found that use of GLP-1 medications can result in high ovulation levels, and according to a meta-analysis conducted, the ovulation rate increased by 55 percent as compared to before. This is definitely a key consideration that can benefit females with PCOS who are trying to get pregnant.
- Weight loss is amplified beyond what the diet achieves – For those individuals with PCOS, a traditional diet regimen is not effective in losing weight because of metabolic changes. An Epic Research study, which uses 300 million electronic medical records, showed that female PCOS patients using GLP-1 agonists (mainly semaglutide) were able to lose 11.5% of their body weight in one year, while female PCOS patients using metformin only lost 1.9%.
Comparing the Three Main GLP-1 Options for PCOS
GLP-1 Medications for PCOS – Comparison
| Medication | Mechanism | Avg. Weight Loss | PCOS Evidence | Key Consideration |
| Semaglutide (Wegovy/Ozempic) | GLP-1 agonist | ~15% body weight | Growing — most prescribed | Best evidence base; widely available |
| Tirzepatide (Zepbound/Mounjaro) | GLP-1 + GIP dual agonist | ~20–22% body weight | Emerging — most powerful metabolically | Superior insulin resistance reduction |
| Liraglutide (Saxenda/Victoza) | GLP-1 agonist | ~6–8% body weight | Longest PCOS-specific trial history | Daily injection; less potent overall |
Semaglutide – The Most Prescribed and Best Studied for PCOS
Of the currently existing GLP-1 receptor agonists that have already been applied in clinical practice, semaglutide, under the brand names Wegovy and Ozempic, is the most commonly prescribed drug for women with PCOS due to its proven effectiveness in treating this disorder.
The clinical trial conducted in 2023 for 27 women diagnosed with PCOS and obesity resistant to lifestyle modification revealed that a low dose of semaglutide (0.5 mg/week) resulted in an average body mass reduction of 11.5 kg in six months, normalization of fasting glucose levels in 80 percent of subjects, and restoration of menstrual cycle in 80 percent of women who responded to medication.
Based on the available literature, semaglutide reduces the body weight of 15 percent in full dose (2.4 mg/week) in PCOS patients, with 68 percent of women experiencing menstrual cycle normalization and 42 percent of women showing reduced hirsutism scores in the respective clinical trials.
Furthermore, semaglutide outperforms other available GLP-1 receptor agonists with the lowest price and insurance coverage compared to other similar drugs in 2026. The newly approved oral form of Wegovy will offer another injection-free alternative for women with a phobia of needles.
For the majority of PCOS patients who meet the requirements in terms of either weight or metabolic criteria, it would be more appropriate to prescribe semaglutide as a prescribed medication from the endocrinologist or OB/GYN, since this GLP-1 agonist is more researched, and it is easier for doctors to prescribe semaglutide as a GLP-1 receptor antagonist.
Tirzepatide – The Most Powerful Metabolic Option
As for tirzepatide (Zepbound for obesity, Mounjaro for diabetes), it is the strongest medicine among the GLP-1 medications available currently because of its action on GLP-1 and GIP receptors.
In the SURMOUNT-1 trial, the use of 15 mg of tirzepatide per week resulted in a decrease in body weight by 22.5% in 72 weeks, that was significantly better than the effect obtained in the case of semaglutide. The result of a head-to-head comparison in the SURMOUNT-5 study demonstrated a decrease in body weight by 20.2% with tirzepatide compared to the 13.7% with semaglutide. However, concerning PCOS, it seems more significant that tirzepatide was able to decrease fasting insulin levels by 2.4 times compared to the placebo in the same trial.
Therefore, considering the importance of insulin resistance for the PCOS pathophysiology, it can be said that better results concerning the reduction of insulin secretion compared to semaglutide are valuable for patients with severe insulin resistance, elevated androgens, and metabolic disturbances.
Lack of activation of GIP receptors under the action of semaglutide also improves fat utilization in adipose tissue and provides extra positive effects on insulin sensitivity via other mechanisms not achievable with the actions of GLP-1. In this regard, additional benefits obtained because of this mechanism might be helpful for women suffering from PCOS associated with serious metabolic issues.
One of the possible limitations in the case of application of tirzepatide in PCOS patients is connected not with efficacy but with costs and availability of this medication, and some clinical studies regarding PCOS conducted concerning tirzepatide. Now, two ongoing studies recruit PCOS patients exclusively to evaluate the impact of tirzepatide treatment. Publication of their results is expected in 2026 and 2027.
For those with considerable insulin resistance, prediabetes, or high PCOS metabolic burden, who can access the new drug, tirzepatide will be much more effective than semaglutide.
Liraglutide – The Longest PCOS Track Record
Liraglutide (Saxenda for weight management and Victoza for type 2 diabetes) has the most extensive history of clinical research in PCOS. Indeed, the drug was used in PCOS trials years before semaglutide or tirzepatide became available. In the Jensterle et al. 2017 study, 40 women were randomized to receive treatment with liraglutide or a placebo for 26 weeks. Participants treated with liraglutide lost 6.8 kg more weight, experienced 23 percent better insulin sensitivity, and achieved normalization of their menstrual cycles (75 percent).
Nevertheless, liraglutide is less effective than semaglutide and tirzepatide. It provides 6 to 8 percent of body weight loss, which is inferior to the results provided by the two newer drugs. Furthermore, liraglutide requires daily administration, whereas semaglutide and tirzepatide can be taken once a week. However, with the availability of the generic version of liraglutide (Saxenda generic) starting in 2025, it can be regarded as a viable alternative for women who do not have access to semaglutide or tirzepatide due to a lack of insurance coverage.
Liraglutide may be more suitable for women with lean PCOS – those who experience insulin resistance but do not have obesity (BMI < 25).
GLP-1 vs. Metformin for PCOS – Which Is Better?
However, how does it compare to GLP-1 receptor antagonists?
According to a meta-analysis study based on the findings of eight randomized trials, GLP-1 RAs were superior to metformin when it comes to insulin resistance improvement and weight reduction measured by BMI and abdominal circumference. The results show the impressive advantage of GLP-1 drugs when it comes to fat reduction; patients lose 11.5 percent of their weight using GLP-1 RAs compared to 1.9 percent in metformin use.
Additionally, GLP-1 drugs and metformin have different ways of affecting the patient’s body; metformin affects the production of glucose in the liver, whereas GLP-1 works through hormones and pathways that involve the stomach, pancreas, and even the brain. It is therefore safe and efficient to take the combination of both, as a prediabetes remission rate reaches 64 percent when the medications are used in combination and only 32 percent when using metformin alone.
In case women have failed to achieve positive results from metformin administration, then GLP-1 RAs can be considered as an alternative solution.
Important Considerations for Women With PCOS
- GLP-1 medications can increase fertility – Non-conceiving patients with PCOS must utilize birth control methods while undergoing treatment with GLP-1 drugs, as these medications have ovulation-enhancing properties; thus, previously anovulatory women would become fertile under the effects of GLP-1s. Also, there are some concerns regarding the efficacy of contraceptive pills due to delayed gastric emptying.
- GLP-1 medications must be stopped before trying to conceive – All currently available GLP-1 agents contraindicate their use during pregnancy. According to the drug label of Wegovy, it is necessary to stop using this medication at least two months before conception due to its rather long half-life.
- Coverage is variable – As PCOS is not yet approved by the FDA, to be eligible for insurance benefits, one should meet other requirements, including a BMI of 30 kg/m2 or higher, or 27 kg/m2 if comorbidities are present. Thus, asking for the calculation of the HOMA-IR at your next appointment is a rational approach; an HOMA-IR index higher than 2.5 in a woman diagnosed with PCOS makes a good argument for prescribing GLP-1s.
For more guidance on GLP-1 coverage and accessing treatment, visit glpweightloss.online.
Frequently Asked Questions
Which GLP-1 is best for PCOS?
There isn’t a GLP-1 that works well for every woman with PCOS. There is more clinical research on Semaglutide (Wegovy). Semaglutide (Wegovy) also happens to be the most commonly used medication. Tirzepatide (Zepbound) provides better results in terms of weight loss and reduction of insulin resistance; therefore, it is likely to be more helpful in the case of metabolic PCOS. Liraglutide (Victoza) has the longest track record in treating PCOS and became more affordable thanks to generics.
Are GLP-1 medications FDA-approved for PCOS?
No. All GLP-1 drugs available for PCOS patients are being prescribed off-label. GLP-1s have FDA approval only for type 2 diabetes and/or obesity. Women with PCOS who qualify for these indications would be able to obtain the medication through them. The use of GLP-1s for PCOS-related metabolic symptoms has clinical support. However, there is currently no FDA approval of GLP-1s for PCOS.
Can GLP-1 medications help restore my period with PCOS?
Indeed, several studies have shown significant improvements in menstrual cycles of women with PCOS after using GLP-1 drugs. For instance, in a semaglutide treatment study, 80 percent of patients who responded positively to the drug showed normalization of their cycles. Similarly, there were also positive findings from liraglutide treatment studies. Normalization of menstrual cycles is said to result from weight loss and improved insulin resistance.
Can GLP-1 medications help with PCOS fertility?
Evidence shows that GLP-1 drugs enhance the rate of ovulation among women with PCOS. One such study found that there was a 55 percent increase in ovulation rate from the baseline. Nevertheless, the use of GLP-1 drugs is not recommended during pregnancy and at least two months before conceiving.
Is tirzepatide better than semaglutide for PCOS?
Tirzepatide results in more weight loss and more aggressive reduction of insulin resistance when compared to semaglutide in general studies. The dual mechanism of action of tirzepatide targeting GIP and GLP-1 receptors can be a benefit to treat insulin resistance associated with PCOS. Unfortunately, PCOS-specific clinical trials of tirzepatide are not abundant at the moment; hence, semaglutide has a more proven role in treating PCOS at the moment due to its cost-effectiveness and accessibility via insurance.
Can I take GLP-1 and metformin together for PCOS?
Yes – this is a strong drug combination. Both metformin and GLP-1 analogs act through different mechanisms; therefore, combination therapy yields better results when compared with monotherapy regarding glycemic control and PCOS treatment. In one study, metformin and GLP-1 drugs caused remission of prediabetes in 64 percent of women diagnosed with PCOS when compared with only 32 percent of patients on metformin alone.
Resources
- https://www.sciencedirect.com/science/article/abs/pii/S1472648319303943
- https://pubmed.ncbi.nlm.nih.gov/37762862/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10661916/
- https://journals.sagepub.com/doi/10.1177/17455057241234530
- https://www.nature.com/articles/s41598-025-99622-4
- https://www.clinicaltrials.gov/study/NCT06222437
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
- https://pubmed.ncbi.nlm.nih.gov/35658024/
- https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
- https://pubmed.ncbi.nlm.nih.gov/28119323/
- https://pubmed.ncbi.nlm.nih.gov/41508932/
- https://clinicaltrials.gov/study/NCT02073929
- https://pubmed.ncbi.nlm.nih.gov/39881036/
- https://www.pcosnutrition.com/glp-1s/
